Diagnosis and therapy of Candida infections: Joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy

Mycoses

Volumn 54, Issue 4, 2011, Pages 279-310

  Ruhnke, Markus ^a   Rickerts, Volker ^b   Cornely, Oliver A ^c   Buchheidt, Dieter ^d   Glöckner, Andreas ^e   Heinz, Werner ^f   Höhl, Rainer ^g   Horré, Regine ^h   Karthaus, Meinolf ⁱ   Kujath, Peter ^j   Willinger, Birgit ^k   Presterl, Elisabeth ^k   Rath, Peter ^l   Ritter, Jörg ^m   Glasmacher, Axel ⁿ   Lass Flörl, Cornelia ^o   Groll, Andreas H ^m  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e BDH Klinik Greifswald GmbH   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g KLINIKUM NÜRNBERG   (Germany)

^h Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

ⁱ Munich Municipal Hospital   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l UNIVERSITY HOSPITAL ESSEN   (Germany)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ UNIVERSITY HOSPITAL BONN   (Germany)

^o INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

Candida; Candidaemia; Candidiasis; Candidosis; Fungal infection; Mycoses

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; EFUNGUMAB; FLUCONAZOLE; FLUCYTOSINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NUCLEOSIDE DERIVATIVE; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ACUTE DISSEMINATED CANDIDOSIS; ARTHRITIS; BLOOD CULTURE; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL VENOUS CATHETER; CHEMOTHERAPY; CHORIORETINITIS; CHRONIC DISSEMINATED CANDIDOSIS; CLINICAL FEATURE; CRYPTOCOCCAL MENINGOENCEPHALITIS; CYSTITIS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; ENDOCARDITIS; ENDOPHTHALMITIS; ESOPHAGUS CANDIDIASIS; FEASIBILITY STUDY; FUNGAL DETECTION; FUNGUS CULTURE; FUNGUS ISOLATION; GRANULOCYTOPENIA; HEPATOSPLENIC CANDIDIASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION RISK; INFECTION SENSITIVITY; INVASIVE CANDIDIASIS; LATEX AGGLUTINATION TEST; MEDICAL LITERATURE; MEDICAL SOCIETY; MENINGITIS; MENINGOENCEPHALITIS; MYCOSIS; NEPHRITIS; NEPHROTOXICITY; NEWBORN PERIOD; NONHUMAN; OPHTHALMOSCOPY; OROPHARYNX CANDIDIASIS; OSTEOMYELITIS; PATHOGENESIS; PERITONITIS; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; REVIEW; TISSUE EXAMINATION; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; MICROBIOLOGICAL TECHNIQUES;

CANDIDA;

EID: 79959210742     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02040.x     Document Type: Review

References (384)

1. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-4.
2. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
3. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006; 7: 495-504.
4. Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR. Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retroviruses 1999; 15: 1619-23.
5. Redding SW, Zellars RC, Kirkpatrick WR et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 1999; 37: 3896-900.
6. Silverman S Jr, Luangjarmekorn L, Greenspan D. Occurrence of oral Candida in irradiated head and neck cancer patients. J Oral Med 1984; 39: 194-6.
7. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996; 10: 365-400.
8. Soysa NS, Samaranayake LP, Ellepola AN. Antimicrobials as a contributory factor in oral candidosis - a brief overview. Oral Dis 2008; 14: 138-43.
9. Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006; 42: 698-702.
10. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990; 28: 2733-8.
11. Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988; 11(Suppl. A): 411-26.
12. Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994; 32: 2299-300.
13. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33: 1959-67.
14. Thorn JL, Gilchrist KB, Sobonya RE, Gaur NK, Lipke PN, Klotz SA. Postmortem candidaemia: marker of disseminated disease. J Clin Pathol 2010; 63: 337-40.
15. Schwesinger G, Junghans D, Schroder G, Bernhardt H, Knoke M. Candidosis and aspergillosis as autopsy findings from 1994 to 2003. Mycoses 2005; 48: 176-80.
16. Donhuijsen K, Pfaffenbach B, Samandari S, Leder LD. Autopsy results of deep mycoses in hematologic neoplasms 1053 patients. Mycoses 1991; 34(Suppl. 1): 25-27.
17. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23: 635-41.
18. Meister H, Heymer B, Schafer H, Haferkamp O. Role of Candida albicans in granulomatous tissue reactions. I. In vitro degradation of C. albicans and immunospecificity of split products. J Infect Dis 1977; 135: 224-34.
19. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108: 88-100.
20. Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 2005; 29: 493-501.
21. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86.
22. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 2003; 124: 2244-55.
23. Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000; 15: 83-90.
24. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-4.
25. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-53.
26. Stoll BJ, Hansen N, Fanaroff AA et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110: 285-91.
27. Saiman L, Ludington E, Pfaller M et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-24.
28. Farmaki E, Evdoridou J, Pouliou T et al. Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol 2007; 24: 127-35.
29. Maksymiuk AW, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP. Systemic candidiasis in cancer patients. Am J Med 1984; 77: 20-27.
30. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med 1981; 71: 363-70.
31. Anaissie EJ, Vartivarian SE, Abi-Said D et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101: 170-6.
32. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
33. Besnard M, Hartmann O, Valteau-Couanet D, Robert MC, Brugieres L, Lemerle J. Systemic Candida infection in pediatric BM autotransplantation: clinical signs, outcome and prognosis. Bone Marrow Transplant 1993; 11: 465-70.
34. Viscoli C, Castagnola E, Giacchino M et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 1999; 35: 770-4.
35. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
36. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
37. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
38. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
39. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
40. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
41. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
42. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
43. Shiboski CH, Wilson CM, Greenspan D, Hilton J, Greenspan JS, Moscicki AB. HIV-related oral manifestations among adolescents in a multicenter cohort study. J Adolesc Health 2001; 29: 109-14.
44. Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998; 12: 447-8.
45. Chiou CC, Groll AH, Mavrogiorgos N, Wood LV, Walsh TJ. Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy. Pediatr Infect Dis J 2002; 21: 388-92.
46. Groll AH, Just-Nuebling G, Kurz M et al. Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 1997; 40: 855-62.
47. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
48. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26: 259-72.
49. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141(Pt 7): 1507-21.
50. de Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-9.
51. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
52. Zaoutis TE, Foraker E, McGowan KL et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005; 52: 295-8.
53. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-302.
54. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
55. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
56. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30.
57. Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70.
58. Zaoutis TE, Heydon K, Localio R, Walsh TJ, Feudtner C. Outcomes attributable to neonatal candidiasis. Clin Infect Dis 2007; 44: 1187-93.
59. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
60. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639-44.
61. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
62. Meunier F. Candidiasis. Eur J Clin Microbiol Infect Dis 1989; 8: 438-47.
63. Ridola V, Chachaty E, Raimondo G et al. Candida infections in children treated with conventional chemotherapy for solid tumors (transplant recipients excluded): The Institut Gustave Roussy Pediatrics Department experience. Pediatr Blood Cancer 2004; 42: 332-7.
64. Samonis G, Rolston K, Karl C, Miller P, Bodey GP. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 1990; 12(Suppl. 3): S369-73.
65. Pagano L, Caira M, Picardi M et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C Report. Clin Infect Dis 2007; 44: 1524-5.
66. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
67. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
68. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487-94.
69. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 52-55.
70. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-90.
71. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-81.
72. Krcmery V Jr, Kovacicova G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagn Microbiol Infect Dis 2000; 36: 7-11.
73. Sendid B, Cotteau A, Francois N et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80.
74. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-5.
75. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 325-31.
76. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43: 4434-40.
77. Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18-24.
78. Borg-von-Zepelin M, Kunz L, Ruchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; 60: 424-8.
79. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007; 51: 1818-21.
80. Aucott JN, Fayen J, Grossnicklas H, Morrissey A, Lederman MM, Salata RA. Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev Infect Dis 1990; 12: 406-11.
81. Krcmery V Jr, Oravcova E, Spanik S et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J Antimicrob Chemother 1998; 41: 373-80.
82. Krcmery V Jr, Mrazova M, Kunova A et al. Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10years in a single cancer institution. Support Care Cancer 1999; 7: 428-31.
83. Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect 1999; 41: 181-94.
84. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
85. Jensen J, Munoz P, Guinea J, Rodriguez-Creixems M, Pelaez T, Bouza E. Mixed fungemia: incidence, risk factors, and mortality in a general hospital. Clin Infect Dis 2007; 44: e109-14.
86. Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818-28.
87. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7(Suppl. 2): 8-24.
88. Bougnoux ME, Dupont C, Turner L, Rouveix E, Dorra M, Nicolas-Chanoine MH. Mixed Candida glabrata and Candida albicans disseminated candidiasis in a heroin addict. Eur J Clin Microbiol Infect Dis 1997; 16: 598-600.
89. Bodey GP, Anaissie EJ, Edwards JE Jr. Definitions of Candida infections. In: Bodey GP (ed.), Candidiasis. New York, USA: Raven Press, Ltd, 1993: 407-8.
90. Reinel D, Plettenberg A, Seebacher C et al. Oral candidiasis. J Dtsch Dermatol Ges 2008; 6: 593-7.
91. Dodd CL, Greenspan D, Katz MH, Westenhouse JL, Feigal DW, Greenspan JS. Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS 1991; 5: 1339-43.
92. Greenspan D, Greenspan JS. HIV-related oral disease. Lancet 1996; 348: 729-33.
93. Plettenberg A, Reisinger E, Lenzner U et al. Oral candidosis in HIV-infected patients. Prognostic value and correlation with immunological parameters. Mycoses 1990; 33: 421-5.
94. Patton LL. Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 182-8.
95. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis 2002; 8(Suppl. 2): 98-109.
96. Rodriguez LJ, Rex JH, Anaissie EJ. Update on invasive candidiasis. Adv Pharmacol 1997; 37: 349-400.
97. Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo PA. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996; 11: 187-290.
98. Mendling W, Seebacher C. Guideline vulvovaginal candidosis: guideline of the German Dermatological Society, the German Speaking Mycological Society and the Working Group for Infections and Infectimmunology of the German Society for Gynecology and Obstetrics. Mycoses 2003; 46: 365-9.
99. Seebacher C, Brasch J, Abeck D et al. Onychomycosis. J Dtsch Dermatol Ges 2007; 5: 61-66.
100. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clin Microbiol Infect 2006; 12: 170-7.
101. Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ. Deeply invasive candidiasis. Infect Dis Clin North Am 2002; 16: 821-35.
102. Pagano L, Mele L, Fianchi L et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 2002; 87: 535-41.
103. Horger M, Brodoefel H, Fritz J, Hartmann J. Imaging in hepatosplenic candidiasis. Rofo 2006; 178: 1051-6.
104. Karthaus M, Huebner G, Geissler RG, Heil G, Ganser A. Hepatic lesions of chronic disseminated systemic candidiasis in leukemia patients may become visible during neutropenia: value of serial ultrasound examinations. Blood 1998; 91: 3087-9.
105. Pestalozzi BC, Krestin GP, Schanz U, Jacky E, Gmur J. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. Blood 1997; 90: 3858-64.
106. dePauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
107. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
108. Solomkin JS. Timing of treatment for nonneutropenic patients colonized with Candida. Am J Surg 1996; 172: 44S-48S.
109. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-85.
110. Playford EG, Lipman J, Kabir M et al. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 2009; 35: 2141-5.
111. Piarroux R, Grenouillet F, Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-9.
112. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.
113. Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-6.
114. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
115. Ruhnke M, Böhme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl. 2): S141-8.
116. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 2007; 45: 3546-8.
117. Horvath LL, George BJ, Hospenthal DR. Detection of fifteen species of Candida in an automated blood culture system. J Clin Microbiol 2007; 45: 3062-4.
118. Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J Clin Microbiol 2004; 42: 115-8.
119. Fricker-Hidalgo H, Lebeau B, Pelloux H, Grillot R. Use of the BACTEC 9240 System with Mycosis-IC/F blood culture bottles for detection of fungemia. J Clin Microbiol 2004; 42: 1855-6.
120. Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994; 32: 975-80.
121. Raad I, Hanna H, Boktour M et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38: 1119-27.
122. Aliyu SH, Enoch DA, Abubakar II et al. Candidaemia in a large teaching hospital: a clinical audit. QJM 2006; 99: 655-63.
123. Ben-Ami R, Weinberger M, Orni-Wasserlauff R et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008; 46: 2222-6.
124. Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004; 140: 18-25.
125. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-90.
126. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: 103-9.
127. Kauffman CA. Candiduria. Clin Infect Dis 2005; 41(Suppl. 6): S371-6.
128. Meersseman W, Lagrou K, Spriet I et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35: 1526-31.
129. Cuenca-Estrella M, Moore CB, Barchiesi F et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003; 9: 467-74.
130. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884-9.
131. Espinel-Ingroff A, Fothergill A, Ghannoum M et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 5243-6.
132. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-80.
133. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35: 982-9.
134. Pfaller MA, Diekema DJ, Rex JH et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-26.
135. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility testing of Yeasts. Approved Standard M27-A3. Clinical and Laboratory Standards Institute 2008; 28: 1-25.
136. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST technical note on voriconazole. Clin Microbiol Infect 2008; 14: 985-7.
137. The European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on fluconazole. Clin Microbiol Infect 2008; 14: 193-5.
138. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39: 40-44.
139. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-58, table.
140. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-47.
141. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-39.
142. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007; 45: 109-11.
143. Shepard JR, Addison RM, Alexander BD et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008; 46: 50-55.
144. Marklein G, Josten M, Klanke U et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 2009; 47: 2912-7.
145. Reiss E, Obayashi T, Orle K, Yoshida M, Zancope-Oliveira RM. Non-culture based diagnostic tests for mycotic infections. Med Mycol 2000; 38(Suppl. 1): 147-59.
146. Mitsutake K, Miyazaki T, Tashiro T et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 1996; 34: 1918-21.
147. Yera H, Sendid B, Francois N, Camus D, Poulain D. Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 2001; 20: 864-70.
148. Sendid B, Poirot JL, Tabouret M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51: 433-42.
149. Sendid B, Caillot D, Baccouch-Humbert B et al. Contribution of the platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003; 41: 4551-8.
150. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 2005; 43: 2181-7.
151. Ibanez-Nolla J, Torres-Rodriguez JM, Nolla M et al. The utility of serology in diagnosing candidosis in non-neutropenic critically ill patients. Mycoses 2001; 44: 47-53.
152. Herent P, Stynen D, Hernando F, Fruit J, Poulain D. Retrospective evaluation of two latex agglutination tests for detection of circulating antigens during invasive candidosis. J Clin Microbiol 1992; 30: 2158-64.
153. Prella M, Bille J, Pugnale M et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005; 51: 95-101.
154. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
155. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
156. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1, 3)-beta-d-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009; 13: 707-12.
157. Buchman TG, Rossier M, Merz WG, Charache P. Detection of surgical pathogens by in vitro DNA amplification. Part I. Rapid identification of Candida albicans by in vitro amplification of a fungus-specific gene. Surgery 1990; 108: 338-46.
158. Einsele H, Hebart H, Roller G et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35: 1353-60.
159. Chryssanthou E, Andersson B, Petrini B, Lofdahl S, Tollemar J. Detection of Candida albicans DNA in serum by polymerase chain reaction. Scand J Infect Dis 1994; 26: 479-85.
160. Fujita S, Lasker BA, Lott TJ, Reiss E, Morrison CJ. Microtitration plate enzyme immunoassay to detect PCR-amplified DNA from Candida species in blood. J Clin Microbiol 1995; 33: 962-7.
161. Garaizar J, Brena S, Bikandi J, Rementeria A, Ponton J. Use of DNA microarray technology and gene expression profiles to investigate the pathogenesis, cell biology, antifungal susceptibility and diagnosis of Candida albicans. FEMS Yeast Res 2006; 6: 987-98.
162. Kasai M, Francesconi A, Petraitiene R et al. Use of quantitative real-time PCR to study the kinetics of extracellular DNA released from Candida albicans, with implications for diagnosis of invasive Candidiasis. J Clin Microbiol 2006; 44: 143-50.
163. Klingspor L, Jalal S. Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. Clin Microbiol Infect 2006; 12: 745-53.
164. Wiesinger-Mayr H, Vierlinger K, Pichler R et al. Identification of human pathogens isolated from blood using microarray hybridisation and signal pattern recognition. BMC Microbiol 2007; 7: 78.
165. Carvalho A, Costa-De-Oliveira S, Martins ML et al. Multiplex PCR identification of eight clinically relevant Candida species. Med Mycol 2007; 45: 619-27.
166. Spiess B, Seifarth W, Hummel M et al. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007; 45: 3743-53.
167. Metwally L, Fairley DJ, Coyle PV et al. Improving molecular detection of Candida DNA in whole blood: comparison of seven fungal DNA extraction protocols using real-time PCR. J Med Microbiol 2008; 57: 296-303.
168. Schabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM, Willinger B. Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J Clin Microbiol 2007; 45: 906-14.
169. White PL, Perry MD, Barnes RA. An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett 2009; 296: 1-10.
170. Mussap M, Molinari MP, Senno E et al. New diagnostic tools for neonatal sepsis: the role of a real-time polymerase chain reaction for the early detection and identification of bacterial and fungal species in blood samples. J Chemother 2007; 19(Suppl. 2): 31-34.
171. Rossetti F, Brawner DL, Bowden R et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995; 20: 801-11.
172. Kappe R, Okeke CN, Fauser C, Maiwald M, Sonntag HG. Molecular probes for the detection of pathogenic fungi in the presence of human tissue. J Med Microbiol 1998; 47: 811-20.
173. Anttila VJ, Farkkila M, Jansson SE et al. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis. Eur J Clin Microbiol Infect Dis 1997; 16: 637-43.
174. Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging 1992; 2: 341-5.
175. Semelka RC, Kelekis NL, Sallah S, Worawattanakul S, Ascher SM. Hepatosplenic fungal disease: diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol 1997; 169: 1311-6.
176. Pastakia B, Shawker TH, Thaler M, O'Leary T, Pizzo PA. Hepatosplenic candidiasis: wheels within wheels. Radiology 1988; 166: 417-21.
177. Anttila VJ, Lamminen AE, Bondestam S et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol 1996; 56: 82-87.
178. Rudolph J, Rodenwaldt J, Ruhnke M, Hamm B, Kopka L. Unusual enhancement pattern of liver lesions in hepatosplenic candidiasis. Acta Radiol 2004; 45: 499-503.
179. Caillot D, Reny G, Solary E et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994; 33: 603-13.
180. Schoffski P, Freund M, Wunder R et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 1998; 317: 379-84.
181. Viviani MA. Flucytosine - what is its future? J Antimicrob Chemother 1995; 35: 241-4.
182. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-18.
183. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15years experience from the UK. J Antimicrob Chemother 2007; 59: 791-3.
184. Glasmacher A, Prentice A. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clin Microbiol Infect 2006; 12(Suppl. 7): 84-90.
185. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
186. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
187. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.
188. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharsmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-91, ix.
189. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
190. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
191. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
192. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
193. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
194. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
195. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
196. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
197. Betts RF, Nucci M, Talwar D et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-84.
198. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006; 44: 760-3.
199. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006; 34: 345-8.
200. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
201. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
202. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005; 6: 1215-29.
203. Arning M, Dresen B, Aul C, Schneider W. Influence of infusion time on the acute toxicity of amphotericin B: results of a randomized double-blind study. Recent Results Cancer Res 1991; 121: 347-52.
204. Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001; 60: 1452-9.
205. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
206. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528-34.
207. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003; 37: 415-25.
208. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
209. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
210. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24hours: randomised controlled trial. BMJ 2001; 322: 579-82.
211. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984; 6: 791-801.
212. Kujath P, Lerch K, Kochendorfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993; 21: 376-82.
213. Abele-Horn M, Kopp A, Sternberg U et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24: 426-32.
214. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-13.
215. Perez-Parra A, Munoz P, Guinea J, Martin-Rabadan P, Guembe M, Bouza E. Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? Intensive Care Med 2009; 35: 707-12.
216. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-72.
217. Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
218. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57: 628-38.
219. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-8.
220. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005; 40(Suppl. 6): S384-91.
221. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-53.
222. Graybill JR, Bocanegra R, Luther M. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis 1995; 14: 700-3.
223. Safdar A, Hanna HA, Boktour M et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101: 2859-65.
224. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
225. Benjamin DK Jr, Miro JM, Hoen B et al. Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD). Scand J Infect Dis 2004; 36: 453-5.
226. Miro JM, del Río A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am 2002; 16: 273, viii.
227. Miro JM, Puig de la BJ, Odds FC et al. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis 1987; 156: 857-8.
228. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21: 994-6.
229. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41(Suppl. 6): S389-93.
230. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
231. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007; 7: 645-57.
232. Wolf HH, Leithauser M, Maschmeyer G et al. Central venous catheter-related infections in hematology and oncology guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2008; 87: 863-76.
233. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, Lopez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother 2003; 47: 3657-9.
234. Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 2001; 20: 42-44.
235. Schinabeck MK, Long LA, Hossain MA et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 2004; 48: 1727-32.
236. Groll AH, Ritter J. Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin Padiatr 2005; 217(Suppl. 1): S37-66.
237. Chiou CC, Walsh TJ, Groll AH. Clinical pharmacology of antifungal agents in pediatric patients. Expert Opin Pharmacother 2007; 8: 2465-89.
238. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 2002; 132: 303-11.
239. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-45.
240. Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093-7.
241. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987-93.
242. Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-24.
243. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005; 24: 167-74.
244. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-6.
245. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43: 1955-60.
246. Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877-84.
247. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.
248. Walsh TJ, Seibel NL, Arndt C et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18: 702-8.
249. Kingo AR, Smyth JA, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J 1997; 16: 1002-3.
250. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003; 22: 603-7.
251. Juster-Reicher A, Leibovitz E, Linder N et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000; 28: 223-6.
252. Würthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005; 49: 5092-8.
253. Heresi GP, Gerstmann DR, Reed MD et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25: 1110-5.
254. Cornely OA, Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-9.
255. Polak A. Combination therapy for systemic mycosis. Infection 1989; 17: 203-9.
256. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301: 126-31.
257. Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs 2007; 21: 293-318.
258. Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274-82.
259. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15years? J Antimicrob Chemother 2006; 57: 384-410.
260. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-32.
261. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-5.
262. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 2007; 50: 196-200.
263. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999; 43: 2148-55.
264. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
265. Hope WW, Mickiene D, Petraitis V et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197: 163-71.
266. Liu KH, Wu CJ, Chou CH et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol 2004; 42: 5950-3.
267. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27: 1711-21.
268. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) 2003; 82: 187-202.
269. Donahue SP, Greven CM, Zuravleff JJ et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101: 1302-9.
270. Benjamin DK Jr, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003; 112: 634-40.
271. Collignon PJ, Sorrell TC. Disseminated candidiasis: evidence of a distinctive syndrome in heroin abusers. Br Med J (Clin Res Ed) 1983; 287: 861-2.
272. Leen CL, Brettle RP. Fungal infections in drug users. J Antimicrob Chemother 1991; 28(Suppl. A): 83-96.
273. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40: e46-e48.
274. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41: e27-E28.
275. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-40.
276. Essman TF, Flynn HW Jr, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28: 185-94.
277. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998; 27: 1130-3.
278. Hiraoka T, Kaji Y, Wakabayashi T, Nanbu PN, Okamoto F, Oshika T. Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits. Cornea 2007; 26: 336-42.
279. Matsumoto Y, Dogru M, Goto E, Fujishima H, Tsubota K. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review. Cornea 2005; 24: 748-53.
280. Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol 2010; 4: 391-405.
281. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318-30.
282. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest 2002; 122: 302-10.
283. Tleyjeh IM, bdel-Latif A, Rahbi H et al. A systematic review of population-based studies of infective endocarditis. Chest 2007; 132: 1025-35.
284. Steinbach WJ, Perfect JR, Cabell CH et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 2005; 51: 230-47.
285. Salamon SA, Fuursted K, Egeblad H, Petersen E, Ott P. Candida albicans tricuspid and pulmonic valve endocarditis: challenge of relapsing risk and role of combined medical treatment and surgery. Scand J Infect Dis 2007; 39: 641-4.
286. Baddley JW, Benjamin DK Jr, Patel M et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 28: 519-29.
287. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32: 50-62.
288. Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103: 25-32.
289. Westling K, Thalme A, Julander I. Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole. Scand J Infect Dis 2005; 37: 310-1.
290. Melamed R, Leibovitz E, Abramson O, Levitas A, Zucker N, Gorodisher R. Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome). Scand J Infect Dis 2000; 32: 86-89.
291. Karatza AA, Dimitriou G, Marangos M et al. Successful resolution of cardiac mycetomas by combined liposomal Amphotericin B with Fluconazole treatment in premature neonates. Eur J Pediatr 2008; 167: 1021-3.
292. Jimenez-Exposito MJ, Torres G, Baraldes A et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004; 39: e70-e73.
293. Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis 2005; 24: 753-5.
294. Williams J, Lye DC. Cure of Candida glabrata native tricuspid valve endocarditis by continuous infusion of conventional amphotericin B in a patient with nephrotic syndrome. Int J Antimicrob Agents 2007; 30: 192-3.
295. Bacak V, Biocina B, Starcevic B, Gertler S, Begovac J. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient - case report and review of literature. J Infect 2006; 53: e11-e14.
296. Lopez-Ciudad V, Castro-Orjales MJ, Leon C et al. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006; 6: 73.
297. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-9.
298. Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Valles J. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114: 146-9.
299. Azoulay E, Cohen Y, Zahar JR et al. Practices in non-neutropenic ICU patients with Candida-positive airway specimens. Intensive Care Med 2004; 30: 1384-9.
300. Kami M, Machida U, Okuzumi K et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002; 117: 40-46.
301. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003; 53: 744-50.
302. Masur H, Rosen PP, Armstrong D. Pulmonary disease caused by Candida species. Am J Med 1977; 63: 914-25.
303. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993; 72: 137-42.
304. el-Ebiary M, Torres A, Fabregas N et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156: 583-90.
305. Kontoyiannis DP, Reddy BT, Torres HA et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34: 400-3.
306. Walsh TJ, Gray WC. Candida epiglottitis in immunocompromised patients. Chest 1987; 91: 482-5.
307. Chiou CC, Seibel NL, Derito FA, Bulas D, Walsh TJ, Groll AH. Concomitant Candida epiglottitis and disseminated Varicella zoster virus infection associated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2006; 28: 757-9.
308. Goldie SJ, Kiernan-Tridle L, Torres C et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Am J Kidney Dis 1996; 28: 86-91.
309. Levine J, Bernard DB, Idelson BA, Farnham H, Saunders C, Sugar AM. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med 1989; 86: 825-7.
310. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2: 1437-40.
311. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
312. Rantala A, Lehtonen OP, Kuttila K, Havia T, Niinikoski J. Diagnostic factors for postoperative candidosis in abdominal surgery. Ann Chir Gynaecol 1991; 80: 323-8.
313. Blot SI, Vandewoude KH, De Waele JJ. Candida peritonitis. Curr Opin Crit Care 2007; 13: 195-9.
314. Kujath P, Hoffmann M, Rodloff A. Antimicrobial and antimycotic therapy of intra-abdominal infections. Chirurg 2008; 79: 295-305.
315. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.
316. Fourtounas C, Marangos M, Kalliakmani P, Savidaki E, Goumenos DS, Vlachojannis JG. Treatment of peritoneal dialysis related fungal peritonitis with caspofungin plus amphotericin B combination therapy. Nephrol Dial Transplant 2006; 21: 236-7.
317. Varisco BM, Benner KW, Prabhakaran P. Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. Ann Pharmacother 2009; 43: 1907-10.
318. Kohli R, Hadley S. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 2005; 19: 831-51.
319. Sealy PI, Nguyen C, Tucci M, Benghuzzi H, Cleary JD. Delivery of antifungal agents using bioactive and nonbioactive bone cements. Ann Pharmacother 2009; 43: 1606-15.
320. Legout L, Assal M, Rohner P, Lew D, Bernard L, Hoffmeyer P. Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis 2006; 38: 728-30.
321. Khazim RM, Debnath UK, Fares Y. Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. Eur Spine J 2006; 15: 1404-10.
322. Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol 2008; 46: 79-83.
323. Yang SC, Shao PL, Hsueh PR, Lin KH, Huang LM. Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation. Acta Paediatr 2006; 95: 629-30.
324. Sili U, Yilmaz M, Ferhanoglu B, Mert A. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. Clin Infect Dis 2007; 45: 897-8.
325. Mouas H, Lutsar I, Dupont B et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005; 40: 1141-7.
326. Karthaus M, Hebart H, Einsele H et al. Long-term survival in patients with acute leukemia and chronic disseminated candidiasis despite minimal antileukemic therapy. Haematologica 2006; 91: 1422-3.
327. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis - a contraindication to marrow transplantation? Blood 1994; 84: 2811-4.
328. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76: 2357-62.
329. Walsh TJ, Whitcomb P, Piscitelli S et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41: 1944-8.
330. Anaissie E, Bodey GP, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91: 142-50.
331. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91: 137-41.
332. Legrand F, Lecuit M, Dupont B et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46: 696-702.
333. Flynn PM, Cunningham CK, Kerkering T et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127: 322-8.
334. Graybill JR, Vazquez J, Darouiche RO et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33-39.
335. Phillips P, De BK, Frechette G et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368-73.
336. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, Di LG. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Gastroenterology 1996; 111: 1169-77.
337. Barbaro G, Barbarini G, Di LG. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Chest 1996; 110: 1507-14.
338. Eichel M, Just-Nubling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 1996; 39(Suppl. 1): 102-6.
339. Saag MS, Fessel WJ, Kaufman CA et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999; 15: 1413-7.
340. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution - effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother 1994; 33: 1071-3.
341. Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 1997; 11: 163-8.
342. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.
343. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227-8.
344. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-86.
345. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-14.
346. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48: 304-9.
347. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-7.
348. Vuffray A, Durussel C, Boerlin P et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994; 8: 708-9.
349. Wilcox CM, Straub RF, Alexander LN, Clark WS. Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Am J Med 1996; 101: 599-604.
350. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227-32.
351. Wilcox CM, Alexander LN, Clark WS, Thompson SE III. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology 1996; 110: 1803-9.
352. Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996; 42: 308-14.
353. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-5.
354. DiNubile MJ, Lupinacci RJ, Berman RS, Sable CA. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses 2002; 18: 903-8.
355. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183-7.
356. Brockmeyer NH, Hantschke D, Olbricht T, Hengge UA, Goos M. Comparative study of the therapy of Candida esophagitis in HIV-1-infected patients with fluconazole or amphotericin B and flucytosine. Mycoses 1991; 34(Suppl. 1): 83-86.
357. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35.
358. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9.
359. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-71.
360. Mendling W, Seebacher C. Guideline for vulvovaginal candidiasis. 6 November 2002 status. Professional Society of Infections and Infection Immunology of the German Society of gynecology and obstetrics and German Language Mycologic Society e.V. J Dtsch Dermatol Ges 2004; 2: 149-52.
361. Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. Expert Opin Drug Saf 2003; 2: 475-83.
362. Wozniak KL, Palmer G, Kutner R, Fidel PL Jr. Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis. Med Mycol 2005; 43: 589-601.
363. Mitchell H. Vaginal discharge - causes, diagnosis, and treatment. BMJ 2004; 328: 1306-8.
364. Kauffman CA, Vazquez JA, Sobel JD et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 14-18.
365. Sobel JD, Kauffman CA, McKinsey D et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 19-24.
366. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500.
367. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007; 44: e46-e49.
368. Lagrotteria D, Rotstein C, Lee CH. Treatment of candiduria with micafungin: a case series. Can J Infect Dis Med Microbiol 2007; 18: 149-50.
369. Seebacher C, Abeck D, Brasch J et al. Candidiasis of the skin. J Dtsch Dermatol Ges 2006; 4: 591-6.
370. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr 2007; 166: 1099-117.
371. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760-7.
372. Plantinga TS, van der Velden WJ, Ferwerda B et al. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009; 49: 724-32.
373. Glocker EO, Hennigs A, Nabavi M et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361: 1727-35.
374. Jayasinghe M, Schmidt S, Walker B, Rocken M, Schaller M. Successful treatment of azole-resistant chronic mucocutaneous candidosis with caspofungin. Acta Derm Venereol 2006; 86: 563-4.
375. Suzuki T, Imamura A. A case of chronic mucocutaneous candidasis cured with micafungin. Kansenshogaku Zasshi 2005; 79: 143-8.
376. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. Clinical and Laboratory Standards Institute 2010; 28: 1-19, Abstract.
377. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998; 26: 461-7.
378. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996; 173: 1208-15.
379. Tuil O., Cohen Y. Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients. Crit Care 2003; 7(Suppl. 2): P131, Abstract.
380. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006; 43: 1083-4.
381. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000; 37: 169-79.
382. Penk A, Pittrow L. Status of fluconazole in the therapy of endogenous Candida endophthalmitis. Mycoses 1998; 41(Suppl. 2): 41-44.
383. Penk A, Pittrow L. Fungal arthritis - a rare complication of systemic candidiasis or orthopedic intervention. Review of therapeutic experience with fluconazole. Mycoses 1998; 41(Suppl. 2): 45-48.
384. Fan-Havard P, O'Donovan C, Smith SM, Oh J, Bamberger M, Eng RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995; 21: 960-5.